TY - JOUR
T1 - Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
AU - Hoff, Nicole A.
AU - Bratcher, Anna
AU - Kelly, J. Daniel
AU - Musene, Kamy
AU - Kompany, Jean Paul
AU - Kabamba, Michel
AU - Mbala-Kingebeni, Placide
AU - Dighero-Kemp, Bonnie
AU - Kocher, Gregory
AU - Elliott, Elizabeth
AU - Reilly, Cavan
AU - Halbrook, Megan
AU - Kebela, Benoit Ilunga
AU - Gadoth, Adva
AU - Mwamba, Guillaume Ngoie
AU - Tambu, Merly
AU - McIlwain, David R.
AU - Mukadi, Patrick
AU - Hensley, Lisa E.
AU - Ahuka-Mundeke, Steve
AU - Rutherford, George W.
AU - Muyembe-Tamfum, Jean Jacques
AU - Rimoin, Anne W.
N1 - Publisher Copyright:
© This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
PY - 2022/2/8
Y1 - 2022/2/8
N2 - Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examines the antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among EVD-exposed and potentially exposed populations in the DRC. We conducted a longitudinal cohort study of 608 rVSVΔG-ZEBOV-GP-vaccinated individuals during an EVD outbreak in North Kivu Province, DRC. Participants provided questionnaires and blood samples at three study visits (day 0, visit 1; day 21, visit 2; and month 6, visit 3). Anti-GP immunoglobulin G (IgG) antibody titers were measured in serum by the Filovirus Animal Nonclinical Group anti-Ebola virus GP IgG enzyme-linked immunosorbent assay. Antibody response was defined as an antibody titer that had increased fourfold from visit 1 to visit 2 and was above four times the lower limit of quantification at visit 2; antibody persistence was defined as a similar increase from visit 1 to visit 3. We then examined demographics for associations with follow-up antibody titers using generalized linear mixed models. A majority of the sample, 87.2%, had an antibody response at visit 2, and 95.6% demonstrated antibody persistence at visit 3. Being female and of young age was predictive of a higher antibody titer postvaccination. Antibody response and persistence after Ebola vaccination was robust in this cohort, confirming findings from outside of the DRC.
AB - Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examines the antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among EVD-exposed and potentially exposed populations in the DRC. We conducted a longitudinal cohort study of 608 rVSVΔG-ZEBOV-GP-vaccinated individuals during an EVD outbreak in North Kivu Province, DRC. Participants provided questionnaires and blood samples at three study visits (day 0, visit 1; day 21, visit 2; and month 6, visit 3). Anti-GP immunoglobulin G (IgG) antibody titers were measured in serum by the Filovirus Animal Nonclinical Group anti-Ebola virus GP IgG enzyme-linked immunosorbent assay. Antibody response was defined as an antibody titer that had increased fourfold from visit 1 to visit 2 and was above four times the lower limit of quantification at visit 2; antibody persistence was defined as a similar increase from visit 1 to visit 3. We then examined demographics for associations with follow-up antibody titers using generalized linear mixed models. A majority of the sample, 87.2%, had an antibody response at visit 2, and 95.6% demonstrated antibody persistence at visit 3. Being female and of young age was predictive of a higher antibody titer postvaccination. Antibody response and persistence after Ebola vaccination was robust in this cohort, confirming findings from outside of the DRC.
KW - Democratic republic of the Congo
KW - Ebola vaccine
KW - Ebola virus disease
KW - Immunogenicity
KW - RVSVΔG-ZEBOV-GP
UR - http://www.scopus.com/inward/record.url?scp=85124060164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124060164&partnerID=8YFLogxK
U2 - 10.1073/pnas.2118895119
DO - 10.1073/pnas.2118895119
M3 - Article
C2 - 35110410
AN - SCOPUS:85124060164
SN - 0027-8424
VL - 119
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 6
M1 - e2118895119
ER -
